Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 55 for Multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

    Scottsdale/Phoenix, AZ

  2. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  3. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  4. A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

    Scottsdale/Phoenix, AZ

  5. Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

    Scottsdale/Phoenix, AZ

  6. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma

    Rochester, MN, Scottsdale/Phoenix, AZ

  7. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration

    Eau Claire, WI, Rochester, MN

  8. A Study to Evaluate the Safety and Effectiveness of Metformin in Combination with Nelfinavair with or without Bortezomib in Relapsed and/or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  9. A Study to Evaluate the Safety, Tolerance and Anti-tumor Activity of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Non-Hodgkin Lymphoma

    Rochester, MN

  10. Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

    Jacksonville, FL

.

Mayo Clinic Footer